80 related articles for article (PubMed ID: 1348452)
21. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
[TBL] [Abstract][Full Text] [Related]
22. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
23. [Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs].
Li CJ; Yu YL; Yang QM; Li Y; Zhang YH; Wang JY
Yao Xue Xue Bao; 2010 Sep; 45(9):1170-6. PubMed ID: 21351575
[TBL] [Abstract][Full Text] [Related]
24. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
25. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets.
Adams MP; Ahdieh H
Drugs R D; 2005; 6(2):91-9. PubMed ID: 15777102
[TBL] [Abstract][Full Text] [Related]
26. Formulation and in vivo evaluation of omeprazole buccal adhesive tablet.
Choi H; Jung J; Yong CS; Rhee C; Lee M; Han J; Park K; Kim C
J Control Release; 2000 Sep; 68(3):405-12. PubMed ID: 10974394
[TBL] [Abstract][Full Text] [Related]
27. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.
Jorga K; Fotteler B; Schmitt M; Nielsen T; Zürcher G; Aitken J
Eur Neurol; 1997; 38(1):59-67. PubMed ID: 9252801
[TBL] [Abstract][Full Text] [Related]
28. Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form.
Tuerck D; Appel-Dingemanse S; Maboudian M; Pommier F; Wang Y; Sedek G
J Clin Pharmacol; 2007 Jan; 47(1):64-9. PubMed ID: 17192503
[TBL] [Abstract][Full Text] [Related]
29. Different HPMC viscosity grades as coating agents for an oral time and/or site-controlled delivery system: a study on process parameters and in vitro performances.
Sangalli ME; Maroni A; Foppoli A; Zema L; Giordano F; Gazzaniga A
Eur J Pharm Sci; 2004 Aug; 22(5):469-76. PubMed ID: 15265517
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
[TBL] [Abstract][Full Text] [Related]
31. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
[TBL] [Abstract][Full Text] [Related]
32. [Preparation of diltiazem hydrochloride delayed-onset, sustained release tablet].
Zhang N; Zhu JB
Yao Xue Xue Bao; 2002 Sep; 37(9):724-7. PubMed ID: 12567900
[TBL] [Abstract][Full Text] [Related]
33. [Release of diltiazem chloride and ibuprofen from hydrophilic matrix tablets].
Vostalová L; Rabisková M; Medvecká G
Ceska Slov Farm; 2003 Nov; 52(6):295-8. PubMed ID: 14661369
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's disease.
Dingemanse J; Kleinbloesem CH; Crevoisier C; Lankhaar G; Gasser UE
Eur Neurol; 1998; 39(2):119-24. PubMed ID: 9520073
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and food interaction of MK-462 in healthy males.
Cheng H; Polvino WJ; Sciberras D; Yogendran L; Cerchio KA; Christie K; Olah TV; McLoughlin D; James I; Rogers JD
Biopharm Drug Dispos; 1996 Jan; 17(1):17-24. PubMed ID: 8991488
[TBL] [Abstract][Full Text] [Related]
36. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic optimisation in the treatment of Parkinson's disease.
Contin M; Riva R; Albani F; Baruzzi A
Clin Pharmacokinet; 1996 Jun; 30(6):463-81. PubMed ID: 8792058
[TBL] [Abstract][Full Text] [Related]
38. [Application of an artificial neural network in the design of sustained-release dosage forms].
Wei XH; Wu JJ; Liang WQ
Yao Xue Xue Bao; 2001 Sep; 36(9):690-4. PubMed ID: 12580110
[TBL] [Abstract][Full Text] [Related]
39. Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets.
Williams RO; Sykora MA; Mahaguna V
AAPS PharmSciTech; 2001 Jun; 2(2):E8. PubMed ID: 14727883
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
